Prognostic value of fluorine-18 fluorodeoxyglucose positron-emission tomography imaging in patients with head and neck squamous cell carcinoma

Head and Neck

Volumn 34, Issue 4, 2012, Pages 462-468

  Querellou, Solène ^a   Abgral, Ronan ^a   Le Roux, Pierre Yves ^a   Nowak, Emmanuel ^b   Valette, Gérald ^a   Potard, Gaël ^a   Le Duc Pennec, Alexandra ^a   Cavarec, Marie Béatrice ^a   Marianovski, Rémi ^a   Salaün, Pierre Yves ^a  

^a BREST UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ EUROPÉENNE DE BRETAGNE   (France)

Author keywords

fluorodeoxyglucose; head and neck cancer; positron emission tomography; predictive factor; SUV

Indexed keywords

FLUORINE 18; FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DRUG UPTAKE; FEMALE; FOLLOW UP; HEAD AND NECK CARCINOMA; HUMAN; LIVER TUMOR; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PULMONARY ARTERY; SQUAMOUS CELL CARCINOMA; TUMOR LOCALIZATION; VASCULAR TUMOR;

AGED; ANALYSIS OF VARIANCE; BIOPSY, NEEDLE; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS;

EID: 84858070886     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21765     Document Type: Article

References (20)

1. Ang KK, Trotti A, Brown BW, et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 51: 571-578.
2. Leemans CR, Tiwari R, Nauta JJP, van der Waal DDS, Snow GB,. Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer 1994; 73: 187-190. (Pubitemid 24012742)
3. Chiesa F, Mauri S, Tradati N, et al. Surfing prognostic factors in head and neck cancer at the millennium. Oral Oncol 1999; 35: 590-596. (Pubitemid 29506986)
4. 18F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 2002; 20: 4199-4208. (Pubitemid 35191022)
5. Tucker R, Coel M, Ko J, Morris P, Druger G, McGuigan P,. Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on patient management: first year's experience in a clinical center. J Clin Oncol 2001; 19: 2504-2508. (Pubitemid 32391221)
6. 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up? J Nucl Med 2009; 50: 24-29.
7. 18F-fluoro-2-deoxy-glucose- positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 1999; 17: 3201-3206. (Pubitemid 29470652)
8. Halfpenny W, Hain SF, Biassoni L, Maisey MN, Sherman JA, McGurk M,. FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer 2002; 86: 512-516. (Pubitemid 34185084)
9. 18F]- D -glucose. Cancer 1998; 82: 2227-2234. (Pubitemid 28240830)
10. Sobin LH, Wittekind Ch,. UICC: TNM classification of malignant tumors, 5th ed. Berlin: Springler-Verlag; 1997.
11. Hall SF, Groome PA, Rothwell D, Dixon PF,. Using TNM staging to predict survival in patients with squamous cell carcinoma of head and neck. Head Neck 1999; 21: 30-38. (Pubitemid 29006453)
12. Salesiotis AN, Cullen KJ,. Molecular markers predictive of response and prognosis in the patient with advanced squamous cell carcinoma of the head and neck: evolution of a model beyond TNM staging. Curr Opin Oncol 2000; 12: 229-239. (Pubitemid 32042736)
13. Reisser C, Eichhorn K, Herold-Mende C, Born AI, Bannasch P,. Expression of facilitative glucose transport proteins during development of squamous cell carcinomas of the head and neck. Int J Cancer 1999; 80: 194-198. (Pubitemid 29001721)
14. 18F]fluoro-2-deoxy- D -glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol 2002; 20: 1398-1404. (Pubitemid 34177448)
15. 18F]fluoro-2-deoxy- D -glucose. Int J Radiat Oncol Biol Phys 2004; 59: 1295-1300. (Pubitemid 38954050)
16. Schwartz DL, Rajendran J, Yueh B, et al. FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg 2004; 130: 1361-1367. (Pubitemid 39603296)
17. 18F-FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx. J Nucl Med 2007; 48: 752-757.
18. 18F]-Fluoro-2-deoxy- D -glucose positron emission tomography as guidance for primary treatment in patients with advanced-stage resectable squamous cell carcinoma of the larynx and hypopharynx. Eur J Surg Oncol 2007; 33: 790-795. (Pubitemid 47029672)
19. Machtay M, Natwa M, Andrel J, et al. Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer. Head Neck 2009; 31: 195-201.
20. Minn H, Lapela M, Klemi PJ, et al. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med 1997; 38: 1907-1911. (Pubitemid 28030920)